P/E ratio for Organovo (ONVO)
P/E ratio as of April 2024 (TTM): -0.4854
According to Organovo's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.485437. At the end of 2022 the company had a P/E ratio of -1.05.
P/E ratio history for Organovo from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.05 | -59.71% |
| 2021 | -2.61 | -46.28% |
| 2020 | -4.86 | 156.59% |
| 2019 | -1.89 | -50.66% |
| 2018 | -3.84 | 3.16% |
| 2017 | -3.72 | -59.31% |
| 2016 | -9.15 | 57.96% |
| 2015 | -5.79 | -71.25% |
| 2014 | -20.1 | -3.58% |
| 2013 | -20.9 | 920.24% |
| 2012 | -2.05 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 General Electric GE | 19.0 | -4,011.59% | 🇺🇸 USA |
 3M MMM | -6.88 | 1,318.06% | 🇺🇸 USA |
 Intuitive Surgical ISRG | 86.9 | -17,997.67% | 🇺🇸 USA |
 United Therapeutics UTHR | 12.1 | -2,593.42% | 🇺🇸 USA |
 Stratasys SSYS | -15.4 | 3,075.57% | 🇮🇱 Israel |
 3D Systems DDD | -3.61 | 643.77% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.